Drug therapy options on the rise: spectacular evidence

Over the last few decades, the incidence of steatotic liver disease has risen in parallel with the increase in obesity, diabetes and other metabolic diseases. It is recommended to screen patients at risk in a targeted manner. Significant progress has been made in the recent past. Recent studies have identified subtypes of MASLD with different cardiovascular risk profiles. In the field of drug therapy for MASH, an important breakthrough has been achieved with the FDA and EMA approval of resmetirome. However, the data situation for subcutaneously administered semaglutide is also promising, as current interim analyses show.